Paraskevi Zagana

ZetaBio Group is an emerging biotechnology research initiative focused on advancing cancer treatment through the development and application of next-generation human-relevant three-dimensional (3D) experimental platforms. The company specializes in patient-derived organoids and organ-on-chip systems that replicate the structural complexity, cellular heterogeneity, and functional responses of human tumors more accurately than conventional laboratory models. By integrating experimental cancer biology with advanced imaging, phenotypic profiling, and data-driven analytical workflows, ZetaBio Group enables predictive drug response testing and translational therapeutic evaluation. These platforms support pharmaceutical development, precision oncology research, and personalized medicine strategies by allowing researchers and clinicians to evaluate treatment responses in biologically relevant human tumor models. ZetaBio Group addresses major global healthcare challenges, including the rising incidence of cancer and the persistently high failure rates of oncology drug development. Through its technology, the company aims to accelerate the discovery of safer and more effective therapies while reducing development costs and improving clinical success rates. Additionally, ZetaBio Group promotes sustainable and ethically responsible biomedical research by supporting the transition toward human-relevant experimental systems that can reduce reliance on animal testing. Through scientific collaboration, research services, and innovation-driven partnerships with academic, clinical, and industrial stakeholders, ZetaBio Group aims to contribute to the next generation of translational oncology tools. The company’s long-term vision is to enable faster therapeutic discovery, support personalized treatment decision-making, and ultimately improve patient outcomes worldwide.